Topic: combination therapy
Arcus Biosciences and Infinity Pharmaceuticals plan to mix their lead programs in triple-combination immunotherapy trials in breast and ovarian cancer.
Early data from Zymeworks showed its lead bispecific antibody hit an overall response rate of 36%, as a single agent for a variety of HER2+ cancers.
Syndax’s entinostat-Keytruda combination may have posted small gains in NSCLC, but an enrichment biomarker could predict increased clinical benefit.
MD Anderson detailed the success of their collaboration with BMS, which connects academic researchers to simultaneous I-O studies in a leukemia pilot.
A pilot showed X4’s anti-PD-1 combination spurred activity in patients that didn’t respond to Opdivo treatment alone, with a drug bought from Sanofi.
The funding will advance its pipelines of synthetic cytokines, designed to improve immuno-oncology treatments.
The buyout gives Promethera control of a TNF receptor 1 inhibitor it hopes will amplify the effects of cell therapy HepaStem.
Novartis foresees next-generation immunotherapies that use biodegradable implants and injectable systems to trigger long-lasting attacks on tumors.
Combining oncolytic viruses with the MS drug Tecfidera could be an effective way to kill a range of cancers, including renal carcinoma, Canadian researchers discovered.
Immuno-oncology startup Arcus Bioscience has got off another impressive round of funding, just over a year after emerging from stealth with $120 million.